Article: B-MS withdraws Ixempra MAA.

Article: Eisai Recieves Positive Opinion for Inovelon(R) Marketing ...
JCN Newswires;  November 20, 2006 ;     700+ words ... ... Lennox-Gastaut Syndrome (LGS) from the Committee for Medicinal Products for Human Use (CHMP), the scientific body of the European ... opinion by the CHMP was announced in response to the Marketing Authorization Application submitted by Eisai in March 2005 for an approval ...

Article: Arixtra gets expanded label in EU.(marketing ...
Pharma Marketletter;  December 1, 2003 ;     700+ words ...The European Commission has granted marketing authorization to Sanofi-Synthelabo and Organon's (a subsidiary ... the European Union's Committee for Proprietary Medicinal Products in July this year. The agent was approved for extended ...

Article: Recommendations on herbal medicinal products in the ...
Nutraceuticals International;  April 1, 1999 ;     700+ words ... ... are considered as medicinal products if they meet the definition ... medicines, like all other medicinal products, need to obtain a marketing authorization before they can be ... Working Group on Herbal Medicinal Products, established in 1997 ...

Article: Germany to classify cinnamon supps to reduce blood sugar as ...
Nutraceuticals International;  January 1, 2007 ;     700+ words ... ... Institute for Medicinal Products and Medical ... classified as medicinal products and required to seek marketing authorization. During ... restricted to medicinal products. Furthermore ... been granted marketing authorization as a plant ...

Article: Committee for Proprietary Medicinal Products ...
PR Newswire;  November 19, 2001 ;     700+ words ... ... for Proprietary Medicinal Products (CPMP), which ... Evaluation of Medicinal Products (EMEA), has ... recommended granting a Marketing Authorization for DYNASTAT ... have a single Marketing Authorization with unified ...

Article: EMEA recommends withdrawal of products containing ...
Adverse Event Reporting News;  July 30, 2007 ;     700+ words ... ... Medicines Agency (EMEA) has recommended the withdrawal of the marketing authorization for medicinal products containing veralipride. EMEA's Committee for Medicinal Products for Human Use (CHMP) concluded that the risks of veralipride ...

Article: Positive CPMP opinion for Pfizer's Macugen.(Committe for ...
Pharma Marketletter;  September 26, 2005 ;     700+ words ... ... union's Committee for Human Medicinal Products has adopted a positive opinion recommending marketing authorization of Macugen (pegaptanib sodium ... European Commission will grant a marketing authorization by the end of the year. AMD ...